Researchers report genomic profiling from more than 110,000 tumors AACR DukeHealth Sagebio DanaFarber VUMChealth genome tumor cancer genetics genome
By Tarun Sai LomteJul 19 2022Reviewed by Danielle Ellis, B.Sc. In a recent study published in Cancer Discovery, researchers analyzed data from the latest public release of the genomics evidence neoplasia information exchange project of the American Association for Cancer Research .
The study and findings In the present study, researchers analyzed data from more than 110,000 tumors. The project has grown from over 18,800 samples in the first release to 110,704 in the latest release. In the 9.1 release, more than half of the specimens were primary tumors, 32% were metastases, and the remaining were local recurrences, hematologic malignancies, or unknown.
Related StoriesThe authors mapped mutations to variant interpretations from OncoKB, an oncology knowledge base, to compute the frequency of clinically actionable alterations in the current dataset of GENIE. They noted that tumors with level 1 or 2 alterations increased to 17%, more than a two-fold increase relative to the previous estimates from 2017.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Study shows that older adults can generate robust, long-lived memory against SARS-CoV-2 following infectionStudy shows that older adults can generate robust, long-lived memory against SARS-CoV-2 following infection SARSCoV2 infection COVID19 coronavirus covid immunity HSN_Sudbury thenosm UConn LancetLongevity
Lire la suite »
Nitazoxanide drug found to be a potent inhibitor of several human coronavirusesNitazoxanide drug found to be a potent inhibitor of several human coronaviruses biorxivpreprint unitorvergata SARSCoV2 COVID19 Coronavirus Nitazoxanide
Lire la suite »
What is the impact of SARS-CoV-2 variant booster vaccinations?What is the impact of SARS-CoV-2 variant booster vaccinations? medrxivpreprint UofR SARSCoV2 COVID19 Booster Vaccination
Lire la suite »